Loading
An updated UK series of placental-site and epithelioid trophoblastic tumours found that more intensive treatment, including high-dose chemotherapy for the worst-prognosis women, improved survival, and refined the factors that predict outcome.
Retrospective analysis of 125 women with placental-site or epithelioid trophoblastic tumour treated in the UK trophoblastic disease centres, extending the earlier Charing Cross series.
Survival improved in the later period with intensified platinum-based chemotherapy and, for women with an interval of 48 months or more since the antecedent pregnancy, high-dose chemotherapy with stem cell rescue; stage, interval and other factors such as hCG level and metastatic pattern were prognostic.
Women with poor-prognosis placental-site or epithelioid trophoblastic tumours should be referred to a specialist centre where intensified and experimental treatments, including immunotherapy, are available.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
Shares Placental-site trophoblastic tumour and epithelioid trophoblastic tumour, Etoposide, Cisplatin.
Shares British Journal of Cancer, Paclitaxel / nab-paclitaxel.
Shares Etoposide, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Etoposide, Paclitaxel / nab-paclitaxel.